Mass Tort brief
English Courts Assert Control Over Landmark Mass Torts
High Court rulings across the £36bn Mariana Dam action, J&J talc claims, and diesel emissions solidify London's role as an independent venue for group litigation.
Mass Tort
The Infected Blood Compensation Authority activated expanded payout tiers — delivering the largest clinical redress settlement in British history.
BackgroundBetween 1970 and 1991, more than 30,000 NHS patients were infected with HIV and hepatitis C through contaminated blood products and transfusions. The Infected Blood Inquiry identified systemic state failure, prompting statutory compensation for infected patients and bereaved families.
- Upgraded assessment rules create supplementary injury severity categories for hepatitis patients who endured interferon therapies, lifting baseline payouts.
- The new regulations expand financial awards for surviving individuals infected as children and elevate awards for bereaved estates, speeding administrative approvals.
- HM Treasury committed over £12.8bn in ringfenced public funding to finance final compensation disbursements through 2027 without statutory caps on individual awards.
Mass Tort
The High Court blocked BHP's bid to pause the Mariana Dam action — refusing to let a legal representation fight derail £36bn in damages hearings.
BackgroundThe collapse of the Fundão tailings dam in 2015 remains Brazil's worst environmental catastrophe, releasing toxic mine waste that killed 19 people. English courts established jurisdiction over BHP in London, previously holding the Anglo-Australian group strictly liable under Brazilian environmental law.
- Mr Justice Constable refused a formal stay in proceedings, ordering an open-court hearing on 5–6 October to determine legal representation.
- A committee of Brazilian claimants voted to replace litigation firm Pogust Goodhead with Hausfeld and Bailey Glasser for the quantum phase.
- Maintaining the trial calendar protects the Stage Two damages timetable covering more than 400,000 affected Brazilian victims across dozens of municipalities.
Mass Tort
The High Court ordered liability trials for UK talc claimants — ensuring Johnson & Johnson faces London court scrutiny despite American bankruptcy maneuvering.
BackgroundOver 2,000 UK claimants allege that long-term cosmetic use of Johnson & Johnson talcum powder caused mesothelioma and ovarian cancer. The US manufacturer has repeatedly attempted to resolve tens of thousands of American claims through Chapter 11 bankruptcy restructuring.
- Mrs Justice Hill directed an initial trial phase to determine whether talc was contaminated and biologically capable of causing cancer.
- The High Court dismissed J&J's broad strike-out bids against patient claimant cohorts, establishing a structured protocol for individuals wishing to discontinue.
- Claimant solicitors confirmed English litigation will press ahead independently regardless of any mass settlement frameworks negotiated by American parent entities.
Mass Tort
The High Court dismissed diesel emissions claims against Ford, Nissan, and Renault — breaking with EU precedent to narrow Britain's largest group action.
BackgroundThe Pan-NOx group litigation brought together 1.6 million UK motorists seeking compensation from car manufacturers over vehicle emissions software. Claimants alleged engine management software unlawfully reduced emissions control during real-world driving compared to regulatory tests.
- Lady Justice Cockerill ruled that unlawful defeat devices require an intentional software purpose to manipulate regulatory test cycles, setting a higher evidentiary bar.
- All defeat-device claims against lead automotive manufacturers Ford, Nissan, and Renault were formally dismissed, removing billions in potential damages.
- Remaining court hearings will focus strictly on damages calculations for remaining brands, substantially reducing the financial exposure of the wider motor sector.
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
